title: Suberanilohydroxamic Acid. Aton Pharma.
abstract: Aton Pharma Inc, under license from the Memorial Sloan-Kettering Cancer Center, is developing suberanilohydroxamic acid (SAHA), a cytodifferentiating agent and histone deacetylase inhibitor, as a potential cancer chemopreventive.
authors.affiliation: Gene Regulation Laboratory, Cancer Immunology Division, Peter MacCallum Cancer Centre, East Melbourne, VIC 3200, Australia. r.johnstone@pmci.unimelb.edu.au
authors.forename: Ricky W
authors.initials: RW
authors.lastname: Johnstone
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D006877:Hydroxamic Acids / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D009369:Neoplasms / Q000188:drug therapy; D013329:Structure-Activity Relationship; D000077337:Vorinostat
chemical_list: D016588:Anticarcinogenic Agents; D004791:Enzyme Inhibitors; D006877:Hydroxamic Acids; D000077337:Vorinostat